Trust
Partners that already trust us
Most funds accept that 60% of their portfolio won't perform. Too often, investors think they're funding growth when they're still funding validation.
2blabs is built to change that ratio — to de-risk deep tech companies between Seed and Series A.
We combine pre-investment analysis with a sector-specific post-investment support — linking capital to milestones.
AI-driven sourcing has commoditised access to startups. At the same time, competition is pushing valuations earlier, while execution and market readiness remain difficult to assess.
The result: capital is often deployed too early relative to startup maturity.
This is particularly visible between Seed and Series A — where most value is lost.
The real bottleneck is not access.
It is knowing when and what to invest in.
They fail because capital and execution are misaligned.
Capital deployed before market readiness — startups spend before they can sell.
Single lump-sum investment instead of staged deployment aligned to execution milestones.
Valuations driven by competitive pressure rather than actual startup readiness.
Execution risk is not addressed post-investment. Without deep, sector-specific execution, portfolio companies are left to navigate critical scale-up challenges alone.
No structured link between capital deployment and verified progress milestones.
This is the gap 2B Labs was built to close.
Different sectors. Different execution risks. Same capital challenge.
A structured de-risking process that helps VC funds determine when to invest, how to structure capital and support execution after investment.
Is this company truly ready for investment?
How and when should capital be deployed?
How do we turn capital into execution, traction and Series A readiness?
Pan-European pipeline across 10 ecosystems, filtered by your investment mandate, sector focus and stage.
We structure each investment across six key dimensions.
Your fund makes the final investment decision — based on the Investment Readiness Assessment, the Investability Report, identified execution gaps, proposed milestones and the capital deployment strategy. The founding team presents in a live pitch and elevator session with our sector experts and your fund. Not a pitch deck alone.
Investment can be structured around validated execution milestones — often through staged capital deployment rather than a single upfront investment.
Once capital is deployed, 2B Labs stays actively involved to build the foundation for scale.
Driving measurable traction and next-round readiness.
Each 2B Labs programme combines a dedicated investment mandate, pan-European sourcing, sector-specific validation, structured investment and post-investment execution.
Tailored nutritional and lifestyle advice. Enhances patient engagement and outcomes.
IoT devices tracking vital signs and health metrics in real-time. Enables continuous data sharing with healthcare providers.
Advanced AI-driven capabilities for remote consultations. Increases healthcare accessibility and efficiency.
Evidence-based software interventions to prevent, manage, or treat medical conditions. Supplements traditional therapies and promotes proactive health management.
Secure and transparent health record handling. Ensures patient privacy and data integrity.
Consumer-friendly tools for early detection of chronic diseases. Integration with digital health records for remote physician review.
AI-driven solutions for managing stress, sleep, and mental health. Tools for cognitive behavioural therapy and mindfulness.
Robotics and AI for physical therapy and post-surgery recovery. Virtual reality platforms to enhance patient mobility and adherence to rehabilitation programmes.
AI-driven platforms for personalised supplementation recommendations. Innovative delivery systems for bioactive compounds.
Devices with fall detection and emergency response capabilities. Cognitive monitoring to detect early signs of dementia or Alzheimer's.
AR-based simulations for healthcare providers to practice procedures. Interactive tools for educating patients on their conditions and treatments.
CE/MDR, FDA and IVDR strategy mapped and integrated from day one — not as an afterthought. Capital tranches aligned with regulatory checkpoints.
First tranche at TRL 6–7. Second tranche triggered by validated clinical data, paid pilots or commercial LOIs — never by time alone.
Hospital procurement, payer reimbursement and public health navigation built into the commercial support. We know how health systems buy.
We bridge the gap between deep scientific expertise and commercial execution capacity — the most common failure point in HealthTech.
Is this the right fit for your fund or your startup?
Tier 1 industrial corporates, utilities and infrastructure players integrated into the programme from the start — not at demo day.
Investment structured to bridge the gap between first pilots and commercial deployment, accounting for infrastructure intensity and long development cycles.
CSRD, EU Green Deal alignment and EU taxonomy mapping embedded in the investor narrative — essential for attracting institutional climate capital.
Commercial agreements and industrial licensing structured to de-risk the scale-up from proof-of-concept to full industrial deployment.
Is this the right fit for your fund or your startup?
Deep tech companies selected through our structured investment process and supported from investment through execution.
A hardware-agnostic AI platform that transforms multimodal data from third-party wearables into clinically validated, patented digital biomarkers — precisely measuring disease progression and response to therapy. Spun off from Eurecat and Hospital Sant Joan de Déu in Barcelona, with first products clinically validated for neuromuscular diseases, frailty and stroke rehabilitation, and CE SaMD IIa certification targeted for 2026.
Visit ephion.health ↗Redefining kidney care through non-invasive diagnostics. Chronic kidney disease is silent and underdiagnosed — fibrosis, its key prognostic factor, still relies on invasive biopsy. DEBIOS' FIBROKIT® is a first-in-class urine-based IVD test that detects and monitors renal fibrosis with biopsy-level precision, based on patented urinary vitronectin and proprietary monoclonal antibodies, validated across 300+ patient samples and more than 30 leading nephrologists.
Visit debiosdx.com ↗The first European SleepTech of its kind. Poor sleep is a silent productivity crisis — costing employers thousands per employee per year — yet no integrated, medical-grade B2B solution existed. SleepZzone is an AI-driven Medical SaaS 360° platform combining clinical assessment, multidisciplinary therapy (doctor, psychologist, physical activity, dentist, nutritionist), gamification and corporate ROI dashboards, delivering an 85% treatment success rate across its network of sleep clinics.
Visit sleepzzone.com ↗AI-enabled peri-operative care and patient optimisation, reducing complications and costs in cancer and surgical care. Traditional prehab requires repeated hospital visits most patients can't sustain — QuestPrehab delivers five AI-supervised care modules (exercise, nutrition, mental preparation, respiratory exercises and patient education) digitally, from referral through to post-op support, already used to optimise over 2,800 patients while cutting 90-day readmissions by half.
Visit questprehab.com ↗The first Digital Molecule for Depression. WakeZ pairs an Apple Watch with a clinically validated, patented haptic protocol that gently reduces REM sleep to ease depressive symptoms — no medication, no side effects. Built on peer-reviewed sleep science, it has shown a 33.8% reduction in patient-reported depressive symptoms across double-blind clinical trials.
Visit wakez.ai ↗The preventive intelligence layer for healthcare. Serena Labs' AI engine turns everyday interactions into early health signals, then acts on them — steering people through acquisition, engagement and retention journeys for insurers and pharma. Proven at scale in Latin America, including a 6× conversion lift for the region's largest health insurer, and now expanding into Spain and the rest of Europe via the Barcelona Health Hub.
Visit serenalabs.io ↗Our team combines deep tech venture building, technology transfer, investment readiness, market acceleration and hands-on company execution.
Former Managing Director of The Collider, the European technology transfer programme. Launched 20+ deep tech spin-offs in four years across HealthTech, ClimateTech and FoodTech, while overseeing 400+ deep tech projects annually.
Journalist specialising in strategic marketing and communications for innovation and technology. Works with companies to translate complex technologies into clear market positioning, commercial narratives and investor communication.
Supports the end-to-end execution of 2B Labs programmes, coordinating startups, partners, investment processes and day-to-day programme operations.
Looking to improve how your fund invests in deep tech? Let's talk.